Literature DB >> 20817921

CRASH syndrome: does it teach us about neurotrophic functions of cell adhesion molecules?

Ling Zhang1.   

Abstract

L1 cell adhesion molecule is a transmembrane glycoprotein of the immunoglobulin superfamily. L1 plays essential roles in normal development of the nervous system, and the mutations in the L1 gene are responsible for CRASH syndrome, a very rare inherited disorder characterized by corpus callosum hypoplasia, mental retardation, adducted thumbs, spastic paraplegia, and hydrocephalus. Here it is hypothesized that in the normal nervous system, the synthesis and neurotrophic function of L1 is controlled by a positive feedback loop, which consists of L1, L1 sheddases, gamma-secretase, L1 extracellular domain (L1ED), L1 cytoplasmic domain (L1CD), and transcriptional factor Pax6. The mutations in L1ED or L1CD will disrupt this feedback loop and inhibit the synthesis and neurotrophic function of L1, therefore contributing to the severe phenotypes in CRASH syndrome. Supported by several lines of experimental evidence, this hypothesis has important implications for the therapy of CRASH syndrome by guiding the development of novel strategies to restore this positive feedback loop to recover the normal function of L1 in CRASH patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20817921     DOI: 10.1177/1073858410365561

Source DB:  PubMed          Journal:  Neuroscientist        ISSN: 1073-8584            Impact factor:   7.519


  2 in total

Review 1.  Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms.

Authors:  John K Fink
Journal:  Acta Neuropathol       Date:  2013-07-30       Impact factor: 17.088

2.  NOG-Derived Peptides Can Restore Neuritogenesis on a CRASH Syndrome Cell Model.

Authors:  Matteo Gasparotto; Yuriko Suemi Hernandez Gomez; Daniele Peterle; Alessandro Grinzato; Federica Zen; Giulia Pontarollo; Laura Acquasaliente; Giorgia Scapin; Elisabetta Bergantino; Vincenzo De Filippis; Francesco Filippini
Journal:  Biomedicines       Date:  2022-01-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.